Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Artelo Biosciences ( (ARTL) ).
On September 9, 2025, Artelo Biosciences, Inc. announced amendments to its bylaws, which include changes to the notice period for special board meetings, elimination of stockholders’ right to take action without a meeting, and updates to shareholder record date provisions. These amendments could impact the company’s governance structure and shareholder engagement, potentially affecting its operations and positioning within the industry.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences, Inc. operates in the biopharmaceutical industry, focusing on the development of therapeutics that target lipid signaling pathways, which are implicated in a variety of diseases.
Average Trading Volume: 700,974
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.46M
Find detailed analytics on ARTL stock on TipRanks’ Stock Analysis page.